Firstly, we’re delighted to announce the first issuance of our patent for our “2nd generation” enhancements to our proprietary drug delivery and administration device, with multiple jurisdictions outstanding.

Secondly, we’re proud to unveil the official trademarked name for our groundbreaking vaginal drug delivery device: CALLAVID®. This marks a pivotal moment as we step up our engagement with the press and establish a strong brand identity.

As we make great strides in our first use case of progesterone delivery for fertility/pregnancy – with significant promise for a wider array of impactful therapeutics – maintaining a reliable and robust IP strategy is vitally important!